Drug-induced liver injury: summary of a single topic clinical research conference

Paul B Watkins1, Leonard B Seeff

  • 1University of North Carolina, Chapel Hill, NC, USA. pbwatkins@med.unc.edu

Hepatology (Baltimore, Md.)
|February 24, 2006
PubMed

Insights

Idiosyncratic drug-induced liver injury (DILI) is poorly understood, likely due to rare genetic and non-genetic factors. The Drug-Induced Liver Injury Network (DILIN) aims to identify these factors and improve understanding of DILI mechanisms.

Area of Science:

  • Hepatology
  • Pharmacogenomics
  • Translational Medicine

Background:

  • Idiosyncratic drug-induced liver injury (DILI) presents a significant challenge in clinical practice due to its unpredictable nature.
  • Understanding the underlying mechanisms of DILI is crucial for improving patient outcomes and drug safety.

Observation:

  • A conference convened basic scientists, translational researchers, and clinicians focused on DILI.
  • The Drug-Induced Liver Injury Network (DILIN), established in 2004, collects extensive clinical and biological data from DILI patients.

Findings:

  • Presentations covered novel hepatotoxicity mechanisms, advanced 'omics' methodologies, and challenges in assessing DILI causality.
  • DILIN's data resources are poised to enable high-priority investigations into DILI's complex etiology.

Implications:

  • Identifying genetic and non-genetic factors contributing to DILI can significantly advance mechanistic understanding.
  • Enhanced knowledge of DILI pathogenesis will facilitate the development of predictive biomarkers and improved diagnostic strategies.

Related Concept Videos

Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...